Mechanism · Research Data · Preclinical Status · Compound Information
FOXO4-DRI — sometimes sold under the supplier trade name "Proxofim" — is a designed D-retro-inverso (DRI) peptide developed to selectively disrupt the interaction between the transcription factor FOXO4 and the tumour suppressor protein p53 inside senescent ("zombie") cells. It is one of the most cited proof-of-concept molecules in senescent-cell-clearance ("senolytic") research.
FOXO4-DRI is preclinical only. No human trials have been conducted or completed. Every published data point on this compound comes from cell culture (in vitro) work and mouse models. There is no human safety or efficacy data, and no regulatory approval of any kind. This should not be extrapolated into an assumption of human safety or effectiveness — mouse and cell-culture results frequently do not translate directly to humans, and this compound has not yet been tested in that context at all.
| Status | Finding |
|---|---|
| Regulatory Approval (FDA/EMA/HPRA) | ✗ Not approved anywhere, for any indication |
| Human RCT Data | ✗ None — no human trials have been conducted |
| Animal Studies | ✔ Mouse models (fast-ageing and naturally aged mice; chemotherapy-treated mice) |
| In Vitro Studies | ✔ Human and mouse senescent cell culture models |
| Development Stage | Early-stage preclinical senolytic research tool compound |
In senescent cells, the transcription factor FOXO4 binds the tumour suppressor p53 in the cell nucleus, effectively sequestering it there. This retention prevents p53 from translocating to the mitochondria, where it would normally trigger apoptosis (programmed cell death). This is part of why senescent cells resist normal apoptotic clearance mechanisms and accumulate with age — they are sometimes described as "zombie cells" for this reason.
FOXO4-DRI is a cell-penetrating peptide engineered to competitively disrupt the FOXO4–p53 interaction, specifically within senescent cells. When this interaction is disrupted, p53 is freed to translocate to the mitochondria and trigger apoptosis selectively in the senescent cell population. Healthy, non-senescent cells have low baseline FOXO4 activity and are reported to be largely spared by this mechanism — this selectivity for senescent over healthy cells is the key feature that distinguishes FOXO4-DRI from a generic cytotoxic agent.
The foundational and most-cited paper in this field is Baar MP et al. (2017), published in Cell, titled "Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging." This work demonstrated that FOXO4-DRI induced selective apoptosis in senescent human and mouse cells in vitro, while largely sparing non-senescent cells.
The same study reported that FOXO4-DRI mitigated doxorubicin (a chemotherapy agent) induced toxicity in mice by clearing the senescent cell burden that accumulates following chemotherapy exposure — a notable preclinical finding for a class of drug-induced senescence relevant to cancer treatment side effects.
Baar et al. reported that FOXO4-DRI restored measures of fitness — including fur density, renal function markers, and running-wheel exercise capacity — in fast-ageing XpdTTD/Ercc1 mutant mice and in naturally aged mice. These are widely cited as some of the most striking reported preclinical findings in the senolytic field, though they remain rodent-model results.
FOXO4-DRI became one of the most frequently cited proof-of-concept molecules in the wider senolytic research field, alongside other approaches such as dasatinib+quercetin and navitoclax. It is generally discussed in the literature as a mechanistically distinct, highly targeted approach to senescent cell clearance, in contrast to broader-acting senolytic drugs.
| Study / Source | Design | Key Finding |
|---|---|---|
| Baar MP et al., 2017 (Cell) | In vitro (human/mouse senescent cells) + mouse models | Selective induction of apoptosis in senescent cells; restored fur density, renal function, and exercise capacity in fast-ageing and naturally aged mice; mitigated doxorubicin-induced toxicity via senescent cell clearance |
| de Keizer PLJ, 2017 (commentary/review) | Review | Contextualises FOXO4-p53 targeting within the broader senescent-cell-clearance research landscape (de Keizer was senior author on Baar et al.) |
| van Deursen JM, 2019 (Science) | Review | Broader review of senolytic therapies and healthy longevity research, situating FOXO4-DRI among other senolytic approaches |
| Kirkland JL & Tchkonia T (senolytics field reviews) | Review | Established senescence-field researchers providing broader context for where FOXO4-DRI sits relative to other senolytics (e.g. dasatinib+quercetin) |
Note: the commercial name "Proxofim" is used by some research-peptide suppliers to refer to synthesised FOXO4-DRI. This is a supplier trade name, not a regulator-approved product name, and its use does not imply any additional validation beyond the preclinical data described above.
⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.
Preclinical mouse-model research protocols only — not dosing recommendations, and not applicable to humans.
| Context | Route | Notes |
|---|---|---|
| Baar et al. 2017 mouse studies | Intraperitoneal (IP) injection | Preclinical rodent dosing only; pharmacokinetics not established in humans; no human protocol exists |
This mouse-model safety observation should not be interpreted as evidence of human safety. Rodent toxicity findings frequently do not predict human outcomes, and a compound with no history of human dosing carries unknown risk by definition. Any claim of "no side effects" for this compound in a human context would be unsupported by the current evidence base.
This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.
Peptide dosing calculator, cycle planner, macro guide and more. No signup required.
Explore Free Tools